With the promise of more widespread gene therapy-based cures on the horizon, the industry looks for new ways to pay for these potential one time only treatments, whose costs can run into the millions. Scrip explores this hot-topic issue, which came to the fore at the annual J.P. Morgan Healthcare Conference, when bluebird bio, Inc. announced a 5-year annual installment payment plan for its gene therapy Lentiglobin. Read the details of the payment proposal’s structure, how other gene therapy players and insurers reacted to it, and what it means for the future of gene therapy, with insights and interviews from Scrip.